Indie Asset Partners LLC Sells 1,208 Shares of Teladoc Health, Inc. (NYSE:TDOC)

Indie Asset Partners LLC lowered its position in shares of Teladoc Health, Inc. (NYSE:TDOC) by 14.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 7,104 shares of the health services provider’s stock after selling 1,208 shares during the period. Teladoc Health comprises about 1.7% of Indie Asset Partners LLC’s portfolio, making the stock its 13th biggest position. Indie Asset Partners LLC’s holdings in Teladoc Health were worth $1,421,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of TDOC. Tradewinds Capital Management LLC grew its position in shares of Teladoc Health by 150.0% in the 3rd quarter. Tradewinds Capital Management LLC now owns 125 shares of the health services provider’s stock valued at $27,000 after buying an additional 75 shares during the last quarter. Capital Advisors Ltd. LLC bought a new stake in shares of Teladoc Health in the 3rd quarter valued at about $30,000. Manchester Financial Inc. grew its position in shares of Teladoc Health by 1,470.0% in the 4th quarter. Manchester Financial Inc. now owns 157 shares of the health services provider’s stock valued at $31,000 after buying an additional 147 shares during the last quarter. Corbenic Partners LLC grew its position in shares of Teladoc Health by 136.4% in the 4th quarter. Corbenic Partners LLC now owns 156 shares of the health services provider’s stock valued at $31,000 after buying an additional 90 shares during the last quarter. Finally, D Orazio & Associates Inc. bought a new stake in shares of Teladoc Health in the 4th quarter valued at about $35,000. Institutional investors and hedge funds own 51.77% of the company’s stock.

In other news, insider Arnnon Geshuri sold 1,750 shares of the firm’s stock in a transaction on Tuesday, February 16th. The stock was sold at an average price of $298.26, for a total value of $521,955.00. Following the completion of the transaction, the insider now directly owns 102,569 shares of the company’s stock, valued at $30,592,229.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Daniel Trencher sold 3,000 shares of the stock in a transaction on Wednesday, February 10th. The stock was sold at an average price of $290.49, for a total value of $871,470.00. Insiders sold 273,363 shares of company stock valued at $61,174,903 over the last ninety days. Corporate insiders own 3.42% of the company’s stock.

Shares of Teladoc Health stock traded down $19.41 during trading hours on Tuesday, reaching $249.35. The company had a trading volume of 153,022 shares, compared to its average volume of 3,090,471. Teladoc Health, Inc. has a one year low of $102.01 and a one year high of $308.00. The business has a fifty day simple moving average of $259.39 and a 200 day simple moving average of $217.85. The company has a debt-to-equity ratio of 0.43, a current ratio of 6.52 and a quick ratio of 6.47. The firm has a market cap of $36.15 billion, a PE ratio of -176.22 and a beta of 0.30.

Several equities research analysts recently commented on TDOC shares. BTIG Research upped their target price on Teladoc Health from $260.00 to $330.00 and gave the company a “buy” rating in a research report on Tuesday, January 26th. Wells Fargo & Company upped their price target on Teladoc Health from $175.00 to $200.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 29th. The Goldman Sachs Group began coverage on Teladoc Health in a research note on Friday, December 4th. They set a “neutral” rating and a $206.00 price target on the stock. Bank of America reissued a “neutral” rating and issued a $245.00 price objective on shares of Teladoc Health in a research note on Tuesday, December 1st. Finally, Stephens downgraded Teladoc Health from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $270.00 to $210.00 in a research note on Monday, December 7th. Thirteen equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $236.39.

Teladoc Health Profile

Teladoc Health, Inc provides virtual healthcare services on a business-to-business basis in the United States and internationally. It covers various clinical conditions, including non-critical, episodic care, chronic, and complicated cases like cancer and congestive heart failure, as well as offers telehealth solutions, expert medical services, behavioral health solutions, guidance and support, and platform and program services.

Recommended Story: What impact do institutional investors have on markets?

Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Health, Inc. (NYSE:TDOC).

Institutional Ownership by Quarter for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.